SY
SYRS.US Syros Pharmaceuticals Inc
- Market cap
- USD 2.68K
- P/E
- -
- P/B
- 10.65x
- ROE
- -
- Dividend yield
- 1,569,325.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is SYRS.US undervalued?
Graham numberThe Graham number of Syros Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syros Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Syros Pharmaceuticals Inc yet.
Syros Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patie…
Full company profileSyros Pharmaceuticals Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Syros Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 317K | 317K | 1.10M | 2.05M | 1.98M | 15.1M | 23.5M | 14.9M | 9.94M | 0.00 |
| Gross Profit | 0.00 | -285K | 317K | 1.10M | 2.05M | 1.98M | 15.1M | 23.5M | 11.9M | 7.68M | -1.32M |
| Operating Income | -13.4M | -29.8M | -48.0M | -54.7M | -64.3M | -77.7M | -82.3M | -99.4M | -136M | -129M | -113M |
| EBITDA | -13.2M | -29.2M | -46.7M | -53.2M | -60.7M | -72.7M | -79.2M | -79.6M | -87.6M | -157M | -37.9M |
| Net Income | -13.4M | -29.8M | -47.7M | -54.0M | -62.3M | -75.4M | -84.0M | -86.6M | -94.7M | -165M | -44.6M |
| EPS | -54 | -120 | -38 | -21 | -19 | -19 | -18 | -14 | -7.49 | -5.81 | -1.13 |
| Balance Sheet | |||||||||||
| Total Assets | 61.5M | 43.6M | 91.3M | 78.5M | 107M | 150M | 213M | 183M | 244M | 168M | 85.0M |
| Total Liabilities | 1.25M | 9.58M | 10.7M | 13.2M | 28.2M | 70.8M | 123M | 97.7M | 117M | 152M | 96.1M |
| Shareholders' Equity | 60.2M | 34.0M | 80.6M | 65.3M | 78.6M | 79.2M | 90.6M | 85.2M | 128M | 16.7M | -11.1M |
| Cash & Short-term Investments | 60.4M | 35.9M | 83.6M | 72.0M | 99.7M | 91.4M | 174M | 130M | 202M | 140M | 58.3M |
| Total Debt | - | 339K | 221K | 53.0K | 31.0K | 25.9M | 66.2M | 65.2M | 63.6M | 62.1M | 60.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.0M | -23.0M | -40.5M | -44.7M | -40.3M | -60.3M | -57.4M | -99.5M | -123M | -110M | -109M |
| Capital Expenditure | 201K | 1.18M | 2.32M | 821K | 1.38M | 12.6M | 3.34M | 1.25M | 1.24M | 272K | 0.00 |
| Free Cash Flow | -12.2M | -24.2M | -42.9M | -45.6M | -41.7M | -72.9M | -60.7M | -101M | -124M | -110M | -109M |
| Ratios | |||||||||||
| ROE | -22.3% | -87.6% | -59.2% | -82.7% | -79.2% | -95.3% | -92.8% | -101.6% | -74.1% | -987.7% | - |
| ROA | -21.8% | -68.3% | -52.3% | -68.8% | -58.3% | -50.3% | -39.4% | -47.3% | -38.7% | -97.9% | -52.4% |
| Net Profit Margin | - | -9,406.3% | -15,060.9% | -4,905.5% | -3,038.0% | -3,806.2% | -556.8% | -368.5% | -636.1% | -1,656.3% | - |
| Debt to Equity | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.33x | 0.73x | 0.76x | 0.50x | 3.73x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Syros Pharmaceuticals Inc dividends
- Dividend yield
- 1,569,325.38%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | USD 42.1M | 1.49 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 433K | 0.09 | - |
| 2019 | USD 161K | 0.04 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Sep 19, 2022.
Who owns Syros Pharmaceuticals Inc
Top funds holding SYRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Institutional Extnd Mkt Idx Tr | 258K | 0.96% | 0.00% | Jan 2025 |
| Fidelity Extended Market Index | 97.6K | 0.36% | -1.08% | Jan 2025 |
| iShares Micro-Cap ETF | 45.8K | 0.17% | 0.00% | Feb 2025 |
| Extended Equity Market Fund K | 44.7K | 0.17% | -1.36% | Dec 2024 |
| Fidelity Total Market Index | 39.8K | 0.15% | 0.00% | Jan 2025 |
| Fidelity Series Total Market Index | 23.7K | 0.09% | 0.00% | Jan 2025 |
| Northern Trust Extended Eq Market Idx | 22.6K | 0.08% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - L | 22.6K | 0.08% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - NL | 16.8K | 0.06% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 13.3K | 0.05% | -1.62% | Dec 2024 |
| Spartan Total Market Index Pool E | 11.9K | 0.04% | 0.00% | Jan 2025 |
| Vanguard U.S. Eq Idx £ Acc | 10.5K | 0.04% | 0.00% | Jan 2025 |
| Fidelity Nasdaq Composite Index | 7.33K | 0.03% | 0.00% | Jan 2025 |
| State St US Extended Mkt Indx NL Cl C | 6.83K | 0.03% | 0.00% | Feb 2025 |
| Extended Equity Market Fund M | 5.81K | 0.02% | +0.97% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T3 | 5.39K | 0.02% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T4 | 5.39K | 0.02% | 0.00% | Dec 2024 |
| 1290 VT Micro Cap K | 4.84K | 0.02% | 0.00% | Jan 2025 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 3.49K | 0.01% | +0.17% | Sep 2024 |
| SSgA U.S. Total Market Index Strategy | 2.80K | 0.01% | +299.29% | Jun 2024 |
Top institutions holding SYRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2.75M | 10.25% | 0.00% | Dec 2024 |
| BlackRock Inc | 277K | 1.03% | +5.99% | Dec 2024 |
| Vanguard Group Inc | 268K | 1.00% | -71.87% | Dec 2024 |
| Omega Fund Management LLC | 251K | 0.94% | 0.00% | Dec 2024 |
| Geode Capital Management, LLC | 196K | 0.73% | -4.12% | Dec 2024 |
| Affinity Asset Advisors, LLC | 150K | 0.56% | 0.00% | Dec 2024 |
| Citigroup Inc | 139K | 0.52% | +20,165.50% | Dec 2024 |
| Qube Research & Technologies | 122K | 0.46% | +57.21% | Dec 2024 |
| TWO SIGMA SECURITIES, LLC | 108K | 0.40% | 0.00% | Dec 2024 |
| Renaissance Technologies Corp | 96.0K | 0.36% | -0.41% | Dec 2024 |
| HRT FINANCIAL LLC | 87.5K | 0.33% | 0.00% | Dec 2024 |
| XTX Topco Ltd | 81.5K | 0.30% | +182.51% | Dec 2024 |
| State Street Corp | 69.4K | 0.26% | 0.00% | Dec 2024 |
| Jane Street Group LLC | 52.9K | 0.20% | 0.00% | Dec 2024 |
| Two Sigma Investments LLC | 48.9K | 0.18% | +71.59% | Dec 2024 |
| UBS Group AG | 45.1K | 0.17% | +169.31% | Dec 2024 |
| Northern Trust Corp | 40.8K | 0.15% | 0.00% | Dec 2024 |
| 1492 Capital Management, LLC | 39.2K | 0.15% | 0.00% | Dec 2024 |
| Virtu Financial LLC | 32.8K | 0.12% | +67.05% | Dec 2024 |
| Baader Bank INC | 22.1K | 0.08% | 0.00% | Dec 2024 |
Syros Pharmaceuticals Inc company profile
- Company name
- Syros Pharmaceuticals Inc
- Ticker
- SYRS.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Fiscal year end
- December
- Address
- 35 CambridgePark Drive, Cambridge, MA, United States, 02140
- Phone
- 617 744 1340
- Website
- syros.com
About Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals Inc management
3- Dr. James E. Bradner M.D.Founder · born 1972
- Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory Board
- Matthew FosterChief Restructuring Officer